Biogen Inc.
Income Statement
| Line Item | FY2009 | FY2008 | FY2007 |
|---|---|---|---|
| Revenue | $4.38B | $4.10B | $3.17B |
| TECFIDERA | — | — | — |
| Interferon (AVONEX+PLEGRIDY combined) | — | — | — |
| AVONEX | — | — | — |
| PLEGRIDY | — | — | — |
| TYSABRI | — | — | — |
| FAMPYRA | — | — | — |
| ZINBRYTA | — | — | — |
| VUMERITY | — | — | — |
| ELOCTATE | — | — | — |
| ALPROLIX | — | — | — |
| FUMADERM | — | — | — |
| SPINRAZA | — | — | — |
| ADUHELM | — | — | — |
| BENEPALI | — | — | — |
| IMRALDI | — | — | — |
| FLIXABI | — | — | — |
| BYOOVIZ | — | — | — |
| TOFIDENCE | — | — | — |
| QALSODY | — | — | — |
| SKYCLARYS | — | — | — |
| ZURZUVAE | — | — | — |
| FUMADERM and ADUHELM (combined) | — | — | — |
| Other Product Revenue | — | — | — |
| Revenue from anti-CD20 therapeutic programs | — | — | — |
| Alzheimer's collaboration revenue | — | — | — |
| Contract manufacturing, royalty and other revenue | — | — | — |
| Cost of Revenue | $382.1M | $402.0M | $335.2M |
| Gross Profit | $4.00B | $3.70B | $2.84B |
| Gross Margin | 91.3% | 90.2% | 89.4% |
| Operating Expenses | |||
| Research & Development | $1.28B | $1.07B | $925.2M |
| SG&A Expense | $911.0M | $925.3M | $776.1M |
| Operating Income | $1.30B | $1.21B | $779.8M |
| Operating Margin | 29.6% | 29.6% | 24.6% |
| Interest Expense | $35.8M | $52.0M | — |
| Pretax Income | $1.33B | $1.16B | $852.2M |
| Income Tax Expense | $355.6M | $365.8M | $272.4M |
| Net Income | $970.1M | $783.2M | $638.2M |
| Net Margin | 22.2% | 19.1% | 20.1% |
| EPS (Basic) | $3.37 | $2.67 | $2.02 |
| EPS (Diluted) | $3.35 | $2.65 | $1.99 |
| Shares Outstanding (Basic) | 287.4M | 292.3M | 315.8M |
| Shares Outstanding (Diluted) | 289.5M | 295.0M | 320.2M |
| Dividends Per Share | — | — | — |